Rezolute Hits 52-Week High On Ersodetug Progress In UpLIFT And SunRIZE Trials For Hyperinsulinism

Rezolute Inc. (RZLT) shares recently reached a 52-week high following FDA alignment on a significantly streamlined Phase III clinical development path for its lead asset, Ersodetug, in tumor-induced hyperinsulinism. The upLIFT study, evaluating Ersodetug, a monoclonal antibody designed to control blood sugar, will now be a single-arm, open-label trial with as few as 16 participants, accelerating topline data to H2 2026 from an initial 48-patient double-blind design. This regulatory clarity, combined with growing anticipation for topline data from the fully enrolled sunRIZE trial for congenital hyperinsulinism in December 2025, positions Ersodetug as a key near-term catalyst for the company.

Analysis

Rezolute Inc. (RZLT) has experienced significant share price appreciation, reaching a 52-week high of $8.06, driven by positive regulatory and clinical developments for its lead asset, Ersodetug. A key catalyst is the FDA's alignment on a streamlined Phase III trial (upLIFT) for Ersodetug in tumor-induced hyperinsulinism. The study's design has been modified from a 48-patient, double-blind, placebo-controlled trial to a more efficient single-arm, open-label format with as few as 16 participants. This change substantially de-risks the program, reduces trial costs, and accelerates the timeline for topline data to the second half of 2026. Further bolstering investor sentiment is the anticipation surrounding the fully enrolled Phase III sunRIZE trial, which is evaluating Ersodetug in congenital hyperinsulinism. With enrollment exceeding its target (62 vs. 56 patients), this trial has a clear, near-term data catalyst expected in December 2025. Additionally, the company's secondary asset, RZ402 for diabetic macular edema, has successfully completed a Phase II study, and the active search for a development partner presents an opportunity for non-dilutive funding and pipeline validation.

Key Decisions for Investors

• Investors should monitor the topline data from the sunRIZE trial in December 2025, as this is the most proximate and significant clinical catalyst for Ersodetug.
• The streamlined design of the upLIFT trial significantly de-risks the path to market for the tumor-induced hyperinsulinism indication, a key positive fundamental change that supports a re-evaluation of the asset's long-term value.
• Consider the recent share price increase from $2.68 to over $8.00, which reflects the market pricing in these positive developments; assess whether current valuation fully captures the de-risked pipeline or if further upside remains.
• Watch for news of a potential partnership for the RZ402 program, as a successful deal could provide non-dilutive capital and further validate the company's development platform.